Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.48 |
| ▸ | ADH1C | P00326 | 1/20 | 0.48 |
| ▸ | ADH1A | P07327 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5240072 | 0.98 | ADH1B (0.46) | ADH1BADH1CADH1A | |
| SCHEMBL5565559 | 0.80 | SMN1; SMN2 (0.40) | ADH1BADH1CADH1A | |
| SCHEMBL8782411 | 0.71 | ADH1B (0.36) | ADH1BADH1CADH1A | |
| SCHEMBL3935406 | 0.71 | ADH1B (0.37) | ADH1BADH1CADH1A | |
| SCHEMBL480913 | 0.69 | — | — | |
| SCHEMBL6671282 | 0.69 | — | — | |
| SCHEMBL4366123 | 0.69 | ADH1B (0.36) | ADH1BADH1CADH1A | |
| SCHEMBL25045216 | 0.67 | FDPS (0.32) | — | |
| SCHEMBL28537860 | 0.67 | TDP1 (0.37) | — | |
| SCHEMBL3121602 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112603-B2 | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | claimed |
| US-20050107340-A1 | Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease | SUGEN, INC. | 2005-05-19 | — | — | US | claimed |
| EP-2982668-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Pharmacyclics LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-1453502-A4 | PHARMACEUTICAL FORMULATIONS COMPRISING INDOLINONE DERIVATIVES | SUGEN INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7112603-B2 | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-7109185-B2 | Pharmaceutical formulations comprising indolinone derivatives | SUGEN, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050107340-A1 | Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease | SUGEN, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1474400-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1453502-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING INDOLINONE DERIVATIVES | Sugen, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6716870-B2 | PROTEIN KINASE MODULATORS | SUGEN, INC. | 2004-04-06 | — | — | US | disclosed |
| US-20030176399-A1 | Pharmaceutical formulations comprising indolinone derivatives | SUGEN INCORPORATED | 2003-09-18 | — | — | US | disclosed |
| WO-2003068756-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)]-6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003045307-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030083363-A1 | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| EP-1283835-A2 | 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | Sugen, Inc. (US) | 2003-02-19 | — | — | EP | disclosed |
| US-6482848-B2 | KINASE INHIBITORS | SUGEN INCORPORATED | 2002-11-19 | — | — | US | disclosed |
| US-20020037878-A1 | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | disclosed |
| WO-2001090103-A9 | 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | SUGEN INC (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001090103-A2 | 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | SUGEN, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037878-A1 | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | DMPK, PNKP, PHKG2 | ADH1B 1202/4885ADH1C 1157/4885ADH1A 1362/4885 |
| US-20030083363-A1 | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | DMPK, PNKP, PHKG2 | ADH1B 1202/4885ADH1C 1157/4885ADH1A 1362/4885 |
| US-20050107340-A1 | Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease | BMP2K, CCNK, DMPK | ADH1B 1807/4885ADH1C 1538/4885ADH1A 1947/4885 |
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | F7, HABP2, F13B | ADH1B 3544/4885ADH1C 3239/4885ADH1A 2388/4885 |
| US-20030176399-A1 | Pharmaceutical formulations comprising indolinone derivatives | DMPK, PLK2, PDPK1 | ADH1B 1598/4885ADH1C 1094/4885ADH1A 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.